The energy supply of cardiomyocytes is provided by glucose and fatty acid (FA) metabolism
Previous inactive GLP-1R TMD structures revealed how allosteric modulators can precisely regulate its function from the extra-helical binding sites 13
In mid to late 2025, around 12.4% of US adults reported taking a GLP-1 medicine specifically for weight loss, up from 5.8% in February 2024, according to Gallup survey data of more than 15,000 adults
Ozempic has been FDA-approved to help manage type 2 diabetes, while Wegovy is approved to manage weight
Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors under clinical evaluation for obesity and type 2 diabetes
However, a small number of Wegovy users have reported experiencing sulfur burps, too